



Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis

Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak & John Mascarenhas

To cite this article: Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Andrew T Kuykendall, Alessandro M Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Alvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak & John Mascarenhas (2022) Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis, *Future Oncology*, 18:27, 2987-2997, DOI: [10.2217/fo-2022-0484](https://doi.org/10.2217/fo-2022-0484)

To link to this article: <https://doi.org/10.2217/fo-2022-0484>



© 2022 The Authors



[View supplementary material](#)



Published online: 11 Aug 2022.



[Submit your article to this journal](#)



Article views: 8320



[View related articles](#)



View Crossmark data [↗](#)



Citing articles: 17 View citing articles [↗](#)

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis

Claire N Harrison¹ , Vikas K Gupta² , Aaron T Gerds³ , Raajit Rampal⁴ , Srđan Verstovsek⁵ , Moshe Talpaz⁶ , Jean-Jacques Kiladjian⁷ , Ruben Mesa⁸ , Andrew T Kuykendall⁹ , Alessandro M Vannucchi¹⁰ , Francesca Palandri¹¹ , Sebastian Grosicki¹² , Timothy Devos¹³ , Eric Jourdan¹⁴ , Marielle J Wondergem¹⁵, Haifa Kathrin Al-Ali¹⁶ , Veronika Buxhofer-Ausch¹⁷ , Alberto Alvarez-Larrán¹⁸ , Andrea Patriarca¹⁹ , Marina Kremyanskaya²⁰ , Adam J Mead²¹ , Sanjay Akhani²², Yuri Sheikine^{‡,23}, Gozde Colak²³ & John Mascarenhas^{*,20} 

¹Guys & St Thomas' NHS Foundation Trust, Guy's Hospital, London, SE1 9RT, UK

²Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, M5G 1Z5, Canada

³Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA

⁴Leukemia Service, Department of Medicine and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁵Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA

⁶Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-5936, USA

⁷Clinical Investigation Center (INSERM CIC 1427), Université Paris Cité and Hôpital Saint-Louis, Paris, 75010, France

⁸Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX 78229-3900, USA

⁹Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

¹⁰Department of Hematology, Azienda Ospedaliero-Universitaria Careggi, Firenze, 50139, Italy

¹¹Department of Hematology, IRCCS Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, 40138, Italy

¹²Department of Hematology and Cancer Prevention, Medical University of Silesia in Katowice, Katowice, 40-055, Poland

¹³Department of Hematology, University Hospitals Leuven & Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, 3000, Belgium

¹⁴Department of Hematology, C.H.U., Nîmes, 30029, France

¹⁵Department of Hematology, Amsterdam University Medical Centers, Amsterdam, 1081 HV, The Netherlands

¹⁶Krukenberg Cancer Center, University Hospital Halle, Halle, 06120, Germany

¹⁷Department of Internal Medicine I with Hematology, Stem Cell Transplantation, Hemostaseology and Medical

Oncology, Ordensklinikum Linz Elisabethinen & Johannes Kepler University Linz, Linz, 4020, Austria

¹⁸Department of Hematology, Hospital Clinic Barcelona, Barcelona, 08036, Spain

¹⁹Hematology Unit, Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara, 28100, Italy

²⁰Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

²¹MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DX, UK

²²MorphoSys AG, Planegg, 82152, Germany

²³Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, MA 02110, USA

*Author for correspondence: john.mascarenhas@mssm.edu


‡Alternative spelling of this author's name is Yuri Sheykin

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy. Patients with MF receive ruxolitinib as the current standard of care, but the depth and durability of responses and the percentage of patients achieving clinical outcome measures are limited; thus, a significant unmet medical need exists. Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF. The aim of this article is to describe the design of the ongoing, global, phase III, double-blind, placebo-controlled MANIFEST-2 study evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naïve MF.

Clinical Trial Registration: NCT04603495 (ClinicalTrials.gov)

Plain language summary: Myelofibrosis (MF) is a rare type of blood cancer that interferes with the process of blood cell production by the bone marrow. In patients with MF, the bone marrow becomes overactive, leading to scarring and subsequently a lack of healthy blood cells being produced. The main symptoms of MF include anemia, fatigue, weakness and pain or discomfort in the abdomen. MF is associated with a shortened life expectancy. The current go-to treatment for MF is ruxolitinib. However, ruxolitinib has shown limited efficacy in improving clinical symptoms long term; so, new safe and effective treatments are needed. Pelabresib is a novel drug currently in clinical development for treating MF. The aim of this article is to describe the design of the ongoing, global phase III MANIFEST-2 study. MANIFEST-2 is evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with MF.

Graphical abstract:



Tweetable abstract: Read up on the ongoing MANIFEST-2 trial evaluating #pelabresib and ruxolitinib in JAKi treatment-naive patients with #myelofibrosis in this recently published #openaccess article

First draft submitted: 11 May 2022; Accepted for publication: 6 July 2022; Published online: 11 August 2022

Keywords: CPI-0610 • JAKi treatment-naive • MANIFEST-2 • myelofibrosis • pelabresib • ruxolitinib

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) that includes primary MF as well as MF that develops after a diagnosis of polycythemia vera or essential thrombocythemia [1,2]. The main hallmarks of overt MF are splenomegaly, disease-related symptoms, cytopenias and bone marrow fibrosis. As such, MF is associated with fatigue, abdominal pain, pruritus, night sweats, weight loss, bone pain, thrombohemorrhagic complications and progressive cytopenias often requiring red blood cell (RBC) transfusions [1,2]. The progressive bone marrow fibrosis associated with MF impairs normal hematopoiesis in the bone marrow, contributing to extramedullary hematopoiesis [1,2].

Approximately 9 of 10 cases of MF are considered intermediate to high risk, categories that are associated with reduced survival (reported median survival for intermediate-1 risk, 6.5–7.8 years; intermediate-2 risk, 2.9–3.6 years; high risk, 1.3–1.8 years) [3,4]. The significant symptom burden, splenomegaly, poor quality of life and reduced survival experienced by these patients are all strongly linked with progressive bone marrow fibrosis [3,5].

Allogeneic stem cell transplantation (ASCT) is currently the only potentially curative approach for MF and can be considered in patients <70 years and with intermediate-2 or high-risk disease [6]. However, few patients are eligible due to the associated morbidity and mortality in this patient population [1], and, as such, ASCT is used in <20% of patients [4]. The JAK inhibitors (JAKis) ruxolitinib [7], fedratinib [8] and pacritinib [9] have been US FDA approved for the treatment of adult patients with intermediate-2 or high-risk MF. All three agents have demonstrated splenic responses and symptom improvement in phase III clinical studies [1,10–13]. While pacritinib is approved for intermediate- or high-risk MF patients with platelets <50 × 10⁹/l [9], ruxolitinib and fedratinib are the current standard of care according to the National Comprehensive Cancer Network guidelines in higher-risk patients with platelets ≥50 × 10⁹/l and ineligible for ASCT [14]. In both COMFORT-I and -II studies [1,10], ruxolitinib performed significantly better than placebo and best available therapy, respectively, in terms of ≥35% spleen volume reduction from baseline (SVR35; 41.9 vs 0.7%; p < 0.001 at week 24 in COMFORT-I; 28 vs 0%,

$p < 0.001$ at week 48 in COMFORT-II) [1,10]. Additionally, in COMFORT-I, the reduction in total symptom score of $\geq 50\%$ from baseline (TSS50) at week 24 was significantly higher for ruxolitinib versus placebo (45.9 vs 5.3%, respectively [$p < 0.001$]) [1]. In the JAKARTA study, both fedratinib 400 mg and 500 mg once daily (QD) performed significantly better than placebo in terms of SVR35 (36 and 40%, respectively, vs 1%; $p < 0.001$) and TSS50 (36 and 34%, respectively, vs 7%, $p < 0.001$) at week 24 [12].

Despite now being an established therapy for MF, treatment with ruxolitinib is subject to a number of limitations, such as failure to obtain a significant reduction in splenomegaly or symptom response, and the development or persistence of clinically significant cytopenias [15–17]. Furthermore, there is typically a gradual loss of response to ruxolitinib over time and a lack of evidence for a long-term effect on disease biology [18]. Median time to treatment discontinuation with ruxolitinib has been found to be less than 1 year in a real-world setting [19]. In turn, discontinuation of ruxolitinib can result in accelerated splenomegaly, ruxolitinib discontinuation syndrome and poor outcomes [20,21]. Additionally, patients who do not derive adequate benefit from ruxolitinib have a poor prognosis and/or overall survival (OS) [19,22,23].

As such, there is an unmet need for treatment options for patients with MF that improve upon the spleen and symptom responses seen with JAKi monotherapy, reduce bone marrow fibrosis associated with MF and ameliorate the cytopenias associated with MF and with ruxolitinib.

MANIFEST-2 trial

Here we describe the rationale and design for the phase III MANIFEST-2 (ClinicalTrials.gov, NCT04603495) trial, which will evaluate the efficacy and safety of pelabresib (CPI-0610) and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naive MF. This study is sponsored by Constellation Pharmaceuticals a MorphoSys Company.

Background & rationale

BET proteins regulate transcription of a set of genes that integrate a diverse array of oncogenic abnormal signals. BET inhibition has the potential to modify multiple critical components of MF pathobiology, including megakaryocyte differentiation and proliferation [24–27]. Bone marrow fibrosis in MF develops as a result of aberrant megakaryopoiesis and expression of proinflammatory cytokines [25–27]. These two processes, heavily influenced by BET-mediated gene regulation, lead to myeloproliferation, cytopenias and reticulin deposition and result in disease-related morbidity and mortality [25,27,28]. More recently, elevated proinflammatory cytokines present in MF have been linked to NF- κ B [26]. Through its effect on the NF- κ B signaling pathway, inhibition of BET proteins can reduce proinflammatory cytokine expression [26,29]. In preclinical murine models of MF, BET inhibition resulted in reduced proinflammatory cytokine levels, spleen weight and bone marrow fibrosis [26].

Pelabresib is an oral, small-molecule investigational BET inhibitor (BETi) that is designed to modify the expression of genes involved in NF- κ B signaling in patients with MF (Figure 1) [25,27,28,30]. Pelabresib has demonstrated the potential to change the natural disease course of MF through several mechanisms, including reprogramming of NF- κ B-controlled gene expression, such as the proinflammatory gene *IL-8* [31]. Pelabresib modulates megakaryopoiesis and key NF- κ B signaling nodes in MF, resulting in reduction in proinflammatory cytokines known to play a role in bone marrow fibrosis. Preclinical studies suggest that a combination of a BETi and JAKi can result in synergistic reduction of splenomegaly, bone marrow fibrosis and proinflammatory cytokines [26]. These findings support the potential complementary activity of pelabresib and a JAKi for MF treatment [26,29].

Pelabresib is currently being investigated in the phase II MANIFEST study (NCT02158858) as a monotherapy in patients with MF who are refractory/intolerant or ineligible for JAKi therapy (arm 1), or in combination with ruxolitinib in patients who have suboptimal or lost response to ruxolitinib (arm 2), or in combination with ruxolitinib in JAKi treatment-naive patients with MF (arm 3).

Data from arm 3 of MANIFEST, which include JAKi treatment-naive patients with MF, show robust responses in spleen volumes and symptoms after 24 weeks of treatment with pelabresib and ruxolitinib [32,33]. The combination of pelabresib and ruxolitinib led to 68% (57/84) of patients achieving SVR35 at week 24 [32], with a median spleen volume reduction of -50%. Most patients reported symptomatic improvement on the Myelofibrosis Symptom Assessment Form (MFSAF), with 56% (46/82) achieving TSS50 at week 24, and a median change in TSS of -59% [32]. Pelabresib in combination with ruxolitinib was generally well tolerated; observed events of thrombocytopenia were mostly of low grade, manageable and reversible [32,33]. Data from arms 1 and 2 of the MANIFEST phase II study indicate that pelabresib treatment can lead to improvements in transfusion dependence




Figure 1. Pelabresib proposed mechanism of action in myelofibrosis.

and hemoglobin levels [34,35]. Additionally, an exploratory analysis across all three arms of MANIFEST has also shown that treatment with pelabresib has positive effects on megakaryocyte differentiation and maturation, and erythropoiesis [32]. Based on these encouraging results, the MANIFEST-2 study was initiated.

Data from the three arms of the MANIFEST study in patients with MF indicate that pelabresib impacts cytokine expression and bone marrow function [34,36]. Overall, the reduction of several plasma cytokines involved in the NF- κ B pathway and proinflammatory signaling during treatment with pelabresib monotherapy or pelabresib and ruxolitinib was rapid and durable [34,36]. A total of 23, 25 and 31% of patients in arm 1 (pelabresib monotherapy in patients refractory or intolerant or ineligible for JAKi therapy), arm 2 (pelabresib in combination with ruxolitinib for MF patients with suboptimal/lost response to ruxolitinib) and arm 3 (pelabresib and ruxolitinib in JAKi treatment-naïve patients), respectively, had achieved ≥ 1 grade improvement in bone marrow fibrosis at week 24 by central pathology review [32,34].

Study design

MANIFEST-2 (NCT04603495) is a global phase III, multicenter, randomized, double-blind, placebo-controlled study of pelabresib and ruxolitinib versus placebo and ruxolitinib in JAKi treatment-naïve patients with MF (Figure 2). Following a screening period of ≤ 28 days, eligible patients are randomized in a 1:1 ratio using a centralized interactive voice response system/interactive web response system to receive either pelabresib and ruxolitinib or placebo and ruxolitinib. Stratification is based on the Dynamic International Prognostic Scoring System (DIPSS) risk category (intermediate-1 vs intermediate-2 vs high), platelet count ($>200 \times 10^9/l$ vs $100\text{--}200 \times 10^9/l$) and spleen volume ($\geq 1800 \text{ cm}^3$ vs $<1800 \text{ cm}^3$).

Pelabresib or matched placebo are administered QD for 14 consecutive days, followed by a 7-day break (21-day cycle). The starting dose for pelabresib/placebo is 125 mg QD for all patients, with subsequent dose increases permitted as per protocol criteria. Ruxolitinib is administered twice daily (BID) for all 21 days of each cycle at either 10 or 15 mg BID, depending on patient baseline platelet counts; dose increases are permitted as per protocol criteria. Patients are treated until disease progression or discontinuation/withdrawal of treatment, and are followed up for progression-free survival (PFS) and OS. Patients enrolled in the placebo and ruxolitinib group, who experience disease progression after 24 weeks of treatment, may be crossed over to the pelabresib and ruxolitinib group. Disease




Figure 2. MANIFEST-2 study design.

BID: Twice daily; CT: Computerized tomography; D: Day; DIPSS: Dynamic International Prognostic Scoring System; ET: Essential thrombocythemia; Int-1: Intermediate-1; Int-2: Intermediate-2; MF: Myelofibrosis; MFSAF: Myelofibrosis Symptom Assessment Form; PO: By mouth; PV: Polycythemia vera; QD: Once daily; SVR35: ≥35% spleen volume reduction from baseline; TSS50: Reduction in total symptom score of ≥50% from baseline. Reproduced with permission from [37].

Table 1. Study population, objectives and end points for MANIFEST-2.

Study population	
Key inclusion criteria	Key exclusion criteria
<ul style="list-style-type: none"> • Age ≥18 years • Confirmed diagnosis of MF (primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF) • Adequate hematologic, renal and hepatic function • Have ≥2 symptoms with an average score ≥3 or an average total score of ≥10 over the 7-day period prior to randomization using the MFSAF v4.0 • Prognostic risk-factor score of intermediate-1 or higher per DIPSS • Spleen volume of ≥450 cm³ • ECOG performance status of ≤2 	<ul style="list-style-type: none"> • Splenectomy or splenic irradiation within 6 months prior to anticipated C1D1 • Chronic or active conditions and/or concomitant medication use that would prohibit participation in trial • Prior treatment with any JAKi or BETi for the treatment of a myeloproliferative neoplasm • Candidate for, and willing to undergo allogeneic HSCT
Study end points	
Primary	Key secondary
Splenic response, defined as a ≥35% reduction from baseline in SVR (SVR35), as measured by MRI or CT, at week 24	TSS response, defined as a ≥50% decrease from baseline in TSS (TSS50), as measured by the MFSAF v4.0, at week 24
Objective	
To determine the efficacy and safety of pelabresib and ruxolitinib compared with placebo and ruxolitinib	
BETi: BET inhibitor; C1D1: Cycle 1 day 1; CT: Computerized tomography; DIPSS: Dynamic International Prognostic Scoring System; ECOG: Eastern Cooperative Oncology Group; HSCT: Hematopoietic stem cell transplant; JAKi: JAK inhibitor; MF: Myelofibrosis; MFSAF: Myelofibrosis Symptom Assessment Form; SVR: Spleen volume reduction; TSS: Tumor symptom score.	

progression for crossover eligibility is defined as progressive splenomegaly with enlargement of spleen volume of ≥25% compared with baseline.

Eligibility criteria

The study population consists of patients ≥18 years of age with a confirmed diagnosis of MF (primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF) with adequate hematologic, renal and hepatic function and a prognostic risk score of intermediate-1 or higher per DIPSS. Patients must also have at least two symptoms with an average score ≥3 or an average total score of ≥10 over the 7-day period prior to randomization using the MFSAF v4.0, spleen volume of ≥450 cm³ and Eastern Cooperative Oncology Group performance status ≤2. Patients will be excluded if they have had splenic irradiation in the previous 6 months or a splenectomy, chronic or active conditions, and/or concomitant medication use that would interfere with study treatment or prior treatment with any JAKi or BETi for treatment of a MPN. A summary of key study eligibility criteria is shown in Table 1.

Planned sample size & study period

Planned enrollment is for up to approximately 400 patients in total (up to 200 in the pelabresib and ruxolitinib group, and up to 200 in the placebo and ruxolitinib group). Study enrollment sites are currently located in the USA, Australia, Canada and Europe (Austria, Belgium, France, Hungary, Italy, The Netherlands, Poland, Spain and UK).

Study procedures

Patient demographics are documented during screening, and a complete medical history is collected, including current/past medical conditions and concomitant medications. The patient's disease status is evaluated by measurement of peripheral blood counts, history/documentation of transfusion requirements, MF-associated symptoms, spleen size by palpation and by MRI and/or computed tomography (CT), and grading of bone marrow fibrosis, as assessed by bone marrow biopsy. Patients are required to complete the MFSAF assessment daily, the Patient Global Impression Scale assessment electronically weekly after the start of study treatment and the EQ-5D assessment electronically weekly during screening and treatment. All patients are assessed for toxicity by the investigator per US National Cancer Institute Common Terminology Criteria for Adverse Events v.5.0. For all treatment-emergent adverse events (TEAEs), the investigator will determine if these can be attributed to either pelabresib or, in the case of Germany, the study drugs. Blood samples are collected for the determination of pelabresib and ruxolitinib concentrations in plasma, and biomarker assessments are completed for each patient at certain timepoints.

Outcome measures/end points

The primary efficacy end point of the current study is splenic response at week 24 versus baseline, defined as SVR35 measured by MRI or CT (Table 1). The key secondary end point is TSS50 at week 24 versus baseline, measured by the MFSAF v4.0. Other secondary end points include percentage change in TSS at week 24 versus baseline, improvement in bone marrow fibrosis by ≥ 1 grade at week 24 versus baseline, SVR35 and TSS50 response at week 48 versus baseline, rate of RBC transfusions over the first 24 weeks of treatment, conversion from RBC transfusion dependence to independence, category change of Patient Global Impression of Change at week 24 versus baseline, survival (PFS and OS), percentage of patients with transformation to acute myeloid leukemia, adverse events of all grades and serious adverse events, population pharmacokinetics assessment and descriptive assessment of ruxolitinib plasma concentrations in the presence or absence of ruxolitinib.

Statistics

Analysis methods

The primary analysis will take place after all randomized patients have either completed their week 24 visit or been prematurely discontinued. Until the primary analysis takes place, patients, investigators and the sponsor will remain blinded to patient allocation to study arms, except for those patients who were enrolled into the crossover portion of the study at or after week 24 and therefore had to be unblinded.

The response rates for SVR35 and TSS50 will be tested sequentially using the Cochran–Mantel–Haenszel test stratified by baseline DIPSS (intermediate-1 vs intermediate-2 vs high), platelet count ($100\text{--}200 \times 10^9/l$ vs $>200 \times 10^9/l$) and spleen volume ($<1800 \text{ cm}^3$ vs $\geq 1800 \text{ cm}^3$). As a result of sequential testing, no multiplicity adjustment will be made.

Sample size

Approximately 400 patients will be enrolled in the study (up to 200 in each treatment group) such that sequential treating of the primary (SVR35) and key secondary (TSS50) end points are adequately powered for 2-group continuity corrected χ^2 test.

Conclusion

The current standard of care for symptomatic patients with newly diagnosed MF is treatment with a JAKi. While pacritinib is approved for intermediate- or high-risk MF patients with platelets $<50 \times 10^9/l$ [9], ruxolitinib and fedratinib are the recommended JAKis in higher-risk patients with platelets $\geq 50 \times 10^9/l$ and ineligible for ASCT [14]. However, JAKis offer limited benefits, and a substantial proportion of patients will discontinue JAKi treatment due to progressive disease and TEAEs, such as anemia and thrombocytopenia [16,17,38]. Patients discontinuing JAKi generally have poor prognosis [19,22,23]. A potential reason for this is that MF is a heterogeneous

and genetically and biologically complex disease, and JAKi monotherapy affects only some of its pathogenic drivers. As such, there is currently an unmet need for new and improved treatment options targeting different pathogenic pathways in MF. Synergistic therapeutic agents such as a rational combination strategy are needed, including agents with a novel mechanism of action with potential for disease-modifying effects leading to overall improvement in the prognosis of MF. Preclinical studies suggest that inhibition of both BET and JAK pathways using a rational combination strategy can result in reduction of splenomegaly, bone marrow fibrosis and mutant allele burden [28], and improve the outcomes currently achieved with JAKi monotherapy.

In arm 3 of the phase II MANIFEST study, the combination of pelabresib and ruxolitinib was well tolerated and demonstrated clinically meaningful durable improvements in spleen volume and symptoms in a JAKi treatment-naive patient population with MF [32,33]. While previous pivotal studies on JAKi monotherapy showed SVR35 response rates of 29–42% at week 24 [1,10–12] in arm 3 of MANIFEST, 68% of patients achieved SVR35 at week 24 [32]. Analysis of long-term follow-up data from COMFORT-I and -II revealed that a reduction in palpable spleen size was associated with prolonged survival, as such promoting spleen reduction as a meaningful clinical trial end point [39]. Furthermore, while real-world ruxolitinib discontinuation is frequent (1-, 2- and 3-year rates of 49%, 71% and 86% [n = 51], respectively) [17,23], as of the most recent data cutoff only 25% (20/81) of patients in MANIFEST arm 3 discontinued pelabresib combined with ruxolitinib within 1 year (three patients ongoing but not yet reached 1 year) despite adverse baseline characteristics.

As in the phase II MANIFEST trial, a lower starting dose of ruxolitinib in cycle 1 (5 mg BID below the recommended dose in the local approved product labeling) will be used in order to enhance tolerability during the first cycle. The ruxolitinib dose will be increased at cycle 2 day 1 (i.e., after 3 weeks) to the target dose levels per approved product labeling as long as prespecified criteria are met. This approach is aligned with clinical practice [40].

The phase III MANIFEST-2 trial is designed to evaluate the efficacy and safety of pelabresib with ruxolitinib in JAKi treatment-naive patients with MF. It is the first study of its kind assessing combination therapy as first-line treatment for patients with MF without prior JAKi exposure. It aims to investigate whether pelabresib in combination with ruxolitinib will result in improved efficacy outcomes compared with ruxolitinib versus placebo [1]. Additionally, assessing rational combination therapy as a first-line treatment option has the potential to lead to a paradigm shift for treatment of MF, favoring upfront combination therapy, without prior JAKi monotherapy failure. MANIFEST-2 was opened for enrollment in November 2020 and, as of the time of this publication, is currently recruiting patients. For additional information on the MANIFEST-2 study please visit the NCT website [41].

Executive summary

Introduction

- Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with constitutional symptoms, splenomegaly, anemia and bone marrow fibrosis.
- Patients with MF experience a significant symptom burden and a reduced life expectancy.
- The current standard-of-care for symptomatic patients with newly diagnosed MF is treatment with a JAK inhibitor (JAKi).
- However, JAKis offer limited benefits, and a substantial proportion of patients will discontinue JAKi treatment due to progressive disease and treatment-emergent adverse events, such as anemia and thrombocytopenia. Patients discontinuing JAKis generally have poor prognosis.
- As such, there is currently an unmet need for new and improved treatment options targeting different pathogenic pathways in MF.

Background & rationale

- Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF.
- Pelabresib is currently being investigated in the phase II MANIFEST study (NCT02158858) as monotherapy in patients with MF who are refractory/intolerant or ineligible for JAKi therapy (arm 1), or in combination with ruxolitinib in patients who have suboptimal or lost response to ruxolitinib (arm 2), or in combination with ruxolitinib in JAKi treatment-naive patients with MF (arm 3).
- Data from arm 3 of MANIFEST show robust responses in spleen volumes and symptoms after 24 weeks of treatment with pelabresib and ruxolitinib. Additionally, an exploratory analysis across all three arms of MANIFEST has shown that treatment with pelabresib has positive effects on megakaryocyte differentiation and maturation, and erythropoiesis. Based on these and other encouraging results, the MANIFEST-2 study was initiated.

MANIFEST-2 study design & planned sample size

- The phase III MANIFEST-2 trial (NCT04603495) is designed to evaluate the efficacy and safety of pelabresib with ruxolitinib in JAKi treatment-naive patients with MF.

- Approximately 400 patients will be enrolled in MANIFEST-2 (up to 200 each in the pelabresib and ruxolitinib and placebo and ruxolitinib treatment groups).

Conclusion

- MANIFEST-2 is the first study of its kind assessing combination therapy as first-line treatment for patients with MF without prior JAKi exposure. It aims to investigate whether pelabresib in combination with ruxolitinib will result in improved efficacy outcomes compared with ruxolitinib versus placebo.
- MANIFEST-2 was opened for enrollment in November 2020 and, as of the time of this publication, is currently recruiting patients.

Supplementary data

An infographic accompanies this paper. To view or download this infographic in your browser please click here: <https://www.futuremedicine.com/doi/suppl/10.2217/fon-2022-0484>

Author contributions

Each co-author listed participated sufficiently in the work to take responsibility for the content and that all those who qualify are listed. Authorship credit is based on (a) substantial contributions to the conception or design of the work or the acquisition, analysis or interpretation of data for the work; and (b) drafting the work or revising it critically for important intellectual content; and (c) final approval of the version to be published; and (d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have met conditions (a), (b), (c) and (d).

Financial & competing interests disclosure

CN Harrison receives research funding from Novartis, Celgene and Constellation Pharmaceuticals a MorphoSys Company, and advisory role and speaker funding from Abbvie, Novartis, Bristol Myers Squibb, Celgene, CTI BioPharma, Gilead, Shire, Roche, Janssen, Promedior, Geron, Galacteo, AOP Orphan Pharmaceuticals and Keros. VK Gupta receives consultancy fees from Novartis, Sierra Oncology and Pfizer, honoraria from Novartis, Bristol Myers Squibb and Incyte, research funding from Novartis and Incyte, and serves as a member on an entity's Board of Directors or advisory committees for Novartis, Sierra Oncology and Bristol Myers Squibb. AT Gerds serves as an advisor to Sierra Oncology, CTI Biopharma, Incyte, Abbvie, Bristol Myers Squibb, MorphoSys, Novartis and PharmaEssentia. R Rampal receives consultancy fees from Constellation Pharmaceuticals a MorphoSys Company, Incyte, Celgene/Bristol Myers Squibb, Novartis, Promedior, CTI BioPharma, Jazz Pharmaceuticals, Blueprint Medicines, Stemline Therapeutics, Galecto, Inc., PharmaEssentia, Abbvie, Sierra Oncology, Disc Medicine and Sumitomo Dainippon Pharma, and research funding from Zentalis Pharmaceuticals, Incyte, Constellation Constellation Pharmaceuticals a MorphoSys Company and Stemline Therapeutics. S Verstovsek receives research funding from Blueprint Medicines Corp, Promedior, PharmaEssentia, Protagonist Therapeutics, CTI BioPharma, Celgene, Genentech, NS Pharma, Ital Pharma, Incyte Corporation, Gilead, Sierra Oncology, Roche, AstraZeneca and Novartis, and serves as a consultant for Celgene, Incyte Corporation, Sierra Oncology, Novartis, Constellation Pharmaceuticals a MorphoSys Company and Pragmatist. M Talpaz serves as an advisor/consultant to Novartis and IMAGO, serves/d on a scientific advisory board for Bristol Myers Squibb and Constellation Pharmaceuticals a MorphoSys Company. R Mesa serves as a consultant for Novartis, Sierra Oncology, LaJolla Pharmaceutical Company and Constellation Pharmaceuticals a MorphoSys Company, and receives research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI BioPharma and Constellation Pharmaceuticals a MorphoSys Company. AT Kuykendall receives research fees from Blueprint Medicines Corp, Protagonist Therapeutics, Celgene/Bristol Myers Squibb, Sierra Oncology and Constellation Pharmaceuticals a MorphoSys Company, served on advisory boards for IMAGO, PharmaEssentia, Novartis, Abbvie, CTI Biopharma and Prelude Pharmaceuticals, and has received speaker fees from Incyte, Novartis and Blueprint Medicines Corp. AM Vannucchi: Receives payment or honoraria from Novartis, Incyte and Bristol Myers Squibb, and participates on a Data Safety Monitoring Board or Advisory board for Novartis, Incyte, AbbVie and Bristol Myers Squibb. F Palandri serves on advisory boards for Novartis, Celgene, AOP Orphan Pharmaceuticals, Incyte, Telios and Sierra Oncology. T Devos performed consultancy for AbbVie, Bristol Myers Squibb–Celgene and Novartis. HK Al-Ali has received consulting fees and honoraria from Novartis, Bristol Myers Squibb and Abbvie, and research funding from Novartis, Bristol Myers Squibb and Incyte. A Alvarez-Larrán has received consulting fees and honoraria from, and participates on, a Data Safety Monitoring Board or Advisory Board, for Novartis, AOP Orphan Pharmaceuticals and Celgene. A Patriarca has received honoraria from Sanofi, Novartis and Incyte, and serves on advisory boards for Sanofi. M Kremyanskaya receives grants/research funding from Incyte, Protagonist Therapeutics, Constellation Pharmaceuticals a MorphoSys Company, Bristol Myers Squibb, Astellas, Astex and Chimerix, and consultancy fees from Protagonist Therapeutics. AJ Mead receives consultancy and honoraria from AbbVie, consultancy fees, honoraria and research funding from Celgene and Bristol Myers Squibb, consultancy fees and honoraria from AbbVie,

and serves on speakers bureau for Novartis. S Akhiani is an employee of MorphoSys AG. Y Sheikine and G Colak are employees of Constellation Pharmaceuticals a MorphoSys Company. J Mascarenhas receives research support paid to the institution from Incyte, CTI BioPharma, Kartos, PharmaEssentia, Abbvie, Novartis, Roche, Merck, Celgene, Bristol Myers Squibb and Geron, and consulting fees from Incyte, Constellation Pharmaceuticals a MorphoSys Company, CTI BioPharma, Roche, PharmaEssentia, Geron, Abbvie, Sierra Oncology, Karyopharm, Novartis, Kartos, Bristol Myers Squibb and Celgene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing and editorial assistance was provided by C Holleywood of LiNK Medical, with funding from Constellation Pharmaceuticals a MorphoSys Company.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations. In addition, for investigations, informed consent has been obtained from the participants involved.

Data sharing statement

As this is a Trial-in-Progress manuscript, study data, the study protocol, the statistical analysis plan and any other study-related documents will not be shared at this time.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

References

Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

1. Verstovsek S, Mesa RA, Gotlib J *et al.* A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N. Engl. J. Med.* 366(9), 799–807 (2012).
2. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. *Int. J. Gen. Med.* 7, 89–101 (2014).
3. Gangat N, Caramazza D, Vaidya R *et al.* DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J. Clin. Oncol.* 29(4), 392–397 (2011).
4. Tefferi A, Lasho TL, Jimma T *et al.* One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clin. Proc.* 87(1), 25–33 (2012).
5. Tefferi A, Nicolosi M, Mudireddy M *et al.* Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia.* 32(5), 1189–1199 (2018).
6. Kroger NM, Deeg JH, Olavarria E *et al.* Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia.* 29(11), 2126–2133 (2015).
7. United States Food & Drug Administration. JAKAFI (ruxolitinib) prescribing information (2021). www.jakafi.com/pdf/prescribing-information.pdf
8. United States Food & Drug Administration. INREBIC (fedratinib) prescribing information (2021). www.celgene.com/content/uploads/inrebic-pi.pdf
9. United States Food & Drug Administration. VONJO (pacritinib) prescribing information (2022). www.ctibiopharma.com/VONJO-USPI.pdf
10. Harrison C, Kiladjan JJ, Al-Ali HK *et al.* JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N. Engl. J. Med.* 366(9), 787–798 (2012).
11. Mesa RA, Kiladjan JJ, Catalano JV *et al.* SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. *J. Clin. Oncol.* 35(34), 3844–3850 (2017).
12. Pardanani A, Harrison C, Cortes JE *et al.* Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. *JAMA. Oncol.* 1(5), 643–651 (2015).
13. Mascarenhas J, Hoffman R, Talpaz M *et al.* Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. *JAMA. Oncol.* 4(5), 652–659 (2018).
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloproliferative neoplasms. Version 1 (2022). https://nccn.org/professionals/physician_gls/pdf/mpn.pdf

15. Gupta V, Cerquozzi S, Foltz L *et al.* Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the Canadian Myeloproliferative Neoplasm Group. *JCO. Oncol. Pract.* 16(7), 351–359 (2020).
16. Al-Ali HK, Griesshammer M, Le Coutre P *et al.* Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. *Haematologica* 101(9), 1065–1073 (2016).
17. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. *Leukemia* 29(2), 498–500 (2015).
18. Ross DM, Babon JJ, Tvorogov D, Thomas D. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. *Haematologica* 106(5), 1244–1253 (2021).
19. Mascarenhas J, Mehra M, He J, Potluri R, Loeffgren C. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. *J. Med. Econ.* 23(7), 721–727 (2020).
20. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. *Am. J. Hematol.* 93(12), 1551–1560 (2018).
21. Kuykendall AT, Shah S, Talati C *et al.* Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. *Ann. Hematol.* 97(3), 435–441 (2018).
22. Newberry KJ, Patel K, Masarova L *et al.* Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood* 130(9), 1125–1131 (2017).
23. Palandri F, Breccia M, Bonifacio M *et al.* Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. *Cancer* 126(6), 1243–1252 (2020).
- **In this study exploring ruxolitinib discontinuation in patients with myelofibrosis (MF), 40.8% of patients had discontinued at 3 years and 51.1% had discontinued at last contact. Common reasons for discontinuation included lack/loss of spleen response, adverse events and disease progression. Survival for patients who discontinued was poor, particularly when discontinuing in blast phase.**
24. Alqahtani A, Choucair K, Ashraf M *et al.* Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. *Future. Sci. OA.* 5(3), FSO372 (2019).
25. Ding N, Hah N, Yu RT *et al.* BRD4 is a novel therapeutic target for liver fibrosis. *Proc. Natl Acad. Sci. USA* 112(51), 15713–15718 (2015).
26. Kleppe M, Koche R, Zou L *et al.* Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. *Cancer Cell.* 33(1), 29–43 e27 (2018).
27. Stratton MS, Haldar SM, Mckinsey TA. BRD4 inhibition for the treatment of pathological organ fibrosis. *F1000Res* 6(F1000 Faculty Rev), 1015 (2017).
28. Kleppe M, Koche R, Zou L *et al.* Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. *Cancer. Cell.* 33(4), 785–787 (2018).
29. Ceribelli M, Kelly PN, Shaffer AL *et al.* Blockade of oncogenic IκappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. *Proc. Natl Acad. Sci. USA* 111(31), 11365–11370 (2014).
30. Albrecht BK, Gehling VS, Hewitt MC *et al.* Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. *J. Med. Chem.* 59(4), 1330–1339 (2016).
- **Pelabresib is a potent and selective benzoisoxazoloazepine bromodomain and extraterminal (BET) inhibitor that attenuates BET-dependent gene expression *in vivo*, and it has demonstrated a correlation between BET-driven reduction in MYC gene expression and tumor growth inhibition in xenograft studies, with an acceptable toxicity profile. Pelabresib was subsequently selected for human clinical studies.**
31. Blum KA, Supko JG, Maris M *et al.* PK and PD assessment of BET inhibitor pelabresib (CPI-0610) in patients with relapsed or refractory lymphoma: findings from a phase I study. Presented at: *63rd ASH Annual Meeting & Exposition*. GA, USA (11–14 December 2021).
32. Verstovsek S, Salama ME, Mascarenhas J *et al.* Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data. Presented at: *63rd ASH Annual Meeting & Exposition*. GA, USA (11–14 December 2021).
33. Mascarenhas J, Harrison C, Patriarca A *et al.* CPI-0610, a bromodomain and extraterminal domain protein (BET) Inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naïve myelofibrosis patients: update of MANIFEST phase 2 study. Presented at: *62nd ASH Annual Meeting & Exposition*. (5–8 December 2020). (Virtual)
34. Kremyanskaya M, Mascarenhas J, Palandri F *et al.* Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis – update of clinical and translational data from the ongoing MANIFEST trial. Presented at: *63rd ASH Annual Meeting & Exposition*. GA, USA (11–14 December 2021).
- **In arm 1 of the MANIFEST study, pelabresib monotherapy demonstrated benefits in terms of spleen volume reduction, symptom reduction, hemoglobin benefit and bone marrow fibrosis improvement in patients with myelofibrosis (MF) who were refractory/resistant, ineligible for or intolerant to JAK inhibitor (JAKi) treatment.**

35. Verstovsek S, Kremyanskaya M, Mascarenhas J *et al*. Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: Interim results from MANIFEST phase 2 study. Presented at: *European Hematology Association 2021 Virtual Congress*. (9–17 June 2021). (Virtual)
- **In arm 3 of the MANIFEST study, pelabresib in combination with ruxolitinib demonstrated efficacy in terms of spleen volume reduction and total symptom score, and was well tolerated in JAKi-naive patients with MF. Decreased megakaryocyte clustering, reduced reticulin density and an increase in erythrocytes were also observed.**
36. Keller P, Cui J, Mertz J *et al*. BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients. Presented at: *European Hematology Association 2021 Virtual Congress*. (9–17 June 2021). (Virtual)
- **Translational data from the MANIFEST study indicate that, in patients with MF, pelabresib impacts both cytokine expression and bone marrow function and shows broad clinical activity regardless of mutation status; these findings along with others suggest that pelabresib contributes to potential disease-modifying effects in MF.**
37. Harrison C, Rampal RK, Gupta V *et al*. MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of pelabresib (CPI-0610) and ruxolitinib versus placebo and ruxolitinib in JAK inhibitor-naive myelofibrosis patients. *HemaSphere*. 6(S3), 1769–1770 (2022).
38. Verstovsek S, Mesa RA, Gotlib J *et al*. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica* 100(4), 479–488 (2015).
- **Long-term follow-up of the phase III COMFORT-I study demonstrated a significant benefit of ruxolitinib versus placebo at 3 years, with improved overall survival, durable reductions in spleen volume and meaningful improvements in quality of life measures in patients with MF.**
39. Verstovsek S, Kantarjian HM, Estrov Z *et al*. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. *Blood* 120(6), 1202–1209 (2012).
40. Talpaz M, Erickson-Viitanen S, Hou K, Hamburg S, Baer MR. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. *J. Hematol. Oncol.* 11(1), 101 (2018).
41. Constellation Pharmaceuticals. Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 (2022). <https://clinicaltrials.gov/ct2/show/NCT04603495>